ANERGIS
Anergis, a clinical-stage biopharmaceutical company, discovers and develops allergy vaccines based on the technology of Contiguous Overlapping Peptides for ultra-fast desensitization. It offers vaccines against birch pollen, ragweed pollen, and house dust mite allergies. Francois Spertini founded Anergis in 2001. Its headquarters in Lausanne in Switzerland.
ANERGIS
Social Links:
Industry:
Biotechnology Health Care Life Science Medical Personal Health
Founded:
2001-01-01
Address:
Epalinges, Vaud, Switzerland
Country:
Switzerland
Website Url:
http://www.anergis.ch
Total Employee:
11+
Status:
Active
Contact:
0041-216519223
Email Addresses:
[email protected]
Total Funding:
49 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF LetsEncrypt Nginx ReCAPTCHA ReCAPTCHA V2 CloudFront Pound Sterling Japanese Yen
Similar Organizations
Current Employees Featured
Founder
Investors List
Renaissance
Renaissance investment in Series C - Anergis
Sunstone Life Science Ventures
Sunstone Life Science Ventures investment in Series C - Anergis
BioMedPartners
BioMedPartners investment in Series C - Anergis
BioMedPartners
BioMedPartners investment in Series B - Anergis
Sunstone Life Science Ventures
Sunstone Life Science Ventures investment in Series B - Anergis
Renaissance
Renaissance investment in Series B - Anergis
Renaissance
Renaissance investment in Series A - Anergis
BioMedPartners
BioMedPartners investment in Series A - Anergis
VINCI CAPITAL
VINCI CAPITAL investment in Series A - Anergis
Sunstone Life Science Ventures
Sunstone Life Science Ventures investment in Series A - Anergis
Official Site Inspections
http://www.anergis.ch
- Host name: 104.247.81.50
- IP address: 104.247.81.50
- Location: Canada
- Latitude: 43.6319
- Longitude: -79.3716
- Timezone: America/Toronto
More informations about "Anergis"
Anergis - Crunchbase Company Profile & Funding
Anergis, a clinical-stage biopharmaceutical company, discovers and develops allergy vaccines based on the technology of Contiguous Overlapping Peptides for ultra-fast desensitization. It …See details»
Anergis Company Profile 2024: Valuation, Funding & Investors
When was Anergis founded? Anergis was founded in 2001. Where is Anergis headquartered? Anergis is headquartered in Epalinges, Switzerland. What is the size of Anergis? Anergis has …See details»
Anergis - Sunstone
Anergis Allergy is the fastest growing chronic condition in the industrialized world. Based on its proprietary Contiguous Overlapping Peptides (COP) technology, …See details»
Anergis Company Profile - Office Locations, Competitors ... - Craft
Dec 1, 2020 Anergis has 5 employees at their 1 location and $49 m in total funding,. See insights on Anergis including office locations, competitors, revenue, financials, executives, …See details»
Anergis | Chemin des Croisettes, Epalinges, VD, …
Jun 1, 2001 Anergis is a clinical stage Swiss biotech developing breakthrough allergy vaccines for ultra-fast and safe desensitisation in only 2 months . Find investment information and connect with Anergis, a Chemin des Croisettes, …See details»
Anergis SA - Epalinges, Switzerland - bionity.com
Dec 22, 2014 Anergis discovers and develops proprietary synthetic allergy vaccines with the aim to provide allergy patients and doctors with a significantly improved treatment option: ultra-fast …See details»
Anergis - Products, Competitors, Financials, Employees, …
Use the CB Insights Platform to explore Anergis's full profile. Technology Vendors; Recent Research ... CH-1066, Switzerland +41 21 651 92 20. Suggest an edit. ... Coherent Market …See details»
Anergis - Overview, News & Similar companies | ZoomInfo.com
May 27, 2020 Anergis contact info: Phone number: +41 216519220 Website: www.anergis.ch What does Anergis do? Anergis SA is a privately held Swiss biopharmaceutical company …See details»
Anergis S.A. - Life-Sciences-Europe.com
Anergis was founded by Professor François Spertini, allergist at the University Hospital of Lausanne, Switzerland. Anergis raised over CHF 55 million from private and institutional …See details»
ANERGIS The Future of Allergy Treatment: Ultra-Fast Desensitization
Company Profile. Industry: Biotechnology Site: anergis.ch Description: Anergis is a clinical-stage biopharmaceutical company based in Switzerland. Anergis discovers and develops proprietary …See details»
Anergis SA - Company Profile & Staff Directory - ContactOut
Anergis SA is a Swiss-based biopharmaceutical company specializing in the discovery and development of novel allergy vaccines targeting the most frequent allergies. Allergies are the …See details»
Anergis - VentureRadar
AllerT, the most advanced COP allergy vaccine of Anergis, has demonstrated excellent safety and immunogenicity. Moreover, vaccinated patients developed a long-term immune memory …See details»
Anergis - Funding, Financials, Valuation & Investors - Crunchbase
Anergis discovers and develops allergy vaccines based on the technology of Contiguous Overlapping Peptides for ultra-fast desensitization. ... How much funding has this organization …See details»
Anergis - Company Profile - Tracxn
Nov 5, 2024 Anergis ranks 66th among 175 active competitors. 62 of its competitors are funded while 31 have exited. Overall, Anergis and its competitors have raised over $4.37B in funding …See details»
Anergis S.A. en liquidation - Zefix
Anergis S.A., à Epalinges, CHE-109.310.720 (FOSC du 25.09.2018, p. 0/1004462505). Selon décision de son assemblée générale du 29 octobre 2020, la société a prononcé sa dissolution. …See details»
Anergis - startupticker.ch
Anergis proprietary Allergy Vaccines are designed to be safe and require treatment of only 2 months, in comparison to existing desensitization methods which require 3-5 years. ... Source: …See details»
Anergis Closes CHF 18 Million Series A Financing Round to …
Mar 28, 2011 Anergis SA is a clinical-stage biopharmaceutical company developing innovative immunotherapies against allergies. Its lead product, called “AllerT” and made of so-called …See details»
Anergis Closes CHF 5 Million Financing Round - startupticker.ch
Startupticker.ch; Hirschmattstrasse 33; CH-6003 Luzern; Tel: +41 41 226 20 80; Fax: +41 41 226 20 89; [email protected]; Submit an event; Submit special offer; Login Register. Cancel …See details»
Anergis Closes Series B Financing Round Totaling CHF 14.5 Million
Anergis has so far raised a total of CHF 44 million in private equity, which includes the latest Series B financing round. The funds will be used to advance Anergis birch allergy vaccine …See details»
Anergis on the way to a second-generation allergen immunotherapy
May 29, 2020 A new immunotherapy based on Anergis Contiguous Overlapping Peptides (COP) linked to Mymetics virosomes, was tested in a therapeutic model of birch pollen allergy. The …See details»